Metabolic Syndrome and Its Potential Effect on Treatment Response to Aripiprazole A Post Hoc Analysis of the Stabilization Phase of a Long-Term, Double-Blind Study in Patients With...

por Kemp, David E., Eudicone, James M., McQuade, Robert D., Chambers, Jessie S., Baker, Ross A.
Publicado 2010

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

por Hobart, Mary, Zhang, Peter, Skuban, Aleksandar, Brewer, Claudette, Hefting, Nanco, Sanchez, Raymond, McQuade, Robert D.
Publicado en J Clin Psychopharmacol (2019)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: a...

por Weiss, Catherine, Weiller, Emmanuelle, Baker, Ross A., Duffy, Ruth A., Gwin, Keva K., Zhang, Peter, McQuade, Robert D.
Publicado en Int Clin Psychopharmacol (2018)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants

por Wong, Dean F., Raoufinia, Arash, Bricmont, Patricia, Brašić, James R., McQuade, Robert D., Forbes, Robert A., Kikuchi, Tetsuro, Kuwabara, Hiroto
Publicado en Eur J Clin Pharmacol (2020)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study

por Peters-Strickland, Timothy, Baker, Ross A, McQuade, Robert D, Jin, Na, Eramo, Anna, Perry, Pamela, Johnson, Brian R, Duca, Anna, Sanchez, Raymond
Publicado en NPJ Schizophr (2015)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study

por Fleischhacker, W. Wolfgang, Hobart, Mary, Ouyang, John, Forbes, Andy, Pfister, Stephanie, McQuade, Robert D., Carson, William H., Sanchez, Raymond, Nyilas, Margareta, Weiller, Emmanuelle
Publicado en Int J Neuropsychopharmacol (2016)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

por Kane, John M., Sanchez, Raymond, Zhao, Joan, Duca, Anna R., Johnson, Brian R., McQuade, Robert D., Eramo, Anna, Baker, Ross A., Peters-Strickland, Timothy
Publicado 2013

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis

por Kane, John M., Zhao, Cathy, Johnson, Brian R., Baker, Ross A., Eramo, Anna, McQuade, Robert D., Duca, Anna R., Sanchez, Raymond, Peters-Strickland, Timothy
Publicado en J Med Econ (2015)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

por Berman, Robert M, Thase, Michael E, Trivedi, Madhukar H, Hazel, James A, Marler, Sabrina Vogel, McQuade, Robert D, Carson, William, Baker, Ross A, Marcus, Ronald N
Publicado 2011

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy

por Nelson, J. Craig, Rahman, Zia, Laubmeier, Kimberly K., Eudicone, James M., McQuade, Robert D., Berman, Robert M., Marcus, Ronald N., Baker, Ross A., Sheehan, John J.
Publicado en CNS Spectr (2014)

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores

por Ismail, Zahinoor, Peters-Strickland, Timothy, Miguelez, Maia, Baker, Ross A., Hertel, Peter, Eramo, Anna, Jin, Na, Perry, Pamela, Sanchez, Raymond, McQuade, Robert D., Kane, John M.
Publicado en J Clin Psychopharmacol (2017)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration

por Raoufinia, Arash, Peters-Strickland, Timothy, Nylander, Anna-Greta, Baker, Ross A., Eramo, Anna, Jin, Na, Bricmont, Patricia, Repella, Jennifer, McQuade, Robert D., Hertel, Peter, Larsen, Frank
Publicado en Int J Neuropsychopharmacol (2017)

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

por Ulcickas Yood, Marianne, DeLorenze, Gerald N, Quesenberry, Charles P, Oliveria, Susan A, Tsai, Ai-Lin, Kim, Edward, Cziraky, Mark J, McQuade, Robert D, Newcomer, John W, L'Italien, Gilbert J
Publicado 2011

Changes in Non-high-density Lipoprotein Cholesterol Levels and Triglyceride/High-density Lipoprotein Cholesterol Ratios among Patients Randomized to Aripiprazole versus Olanzapine

por Newcomer, John W., Meyer, Jonathan M., Baker, Ross A., Eudicone, James M., Pikalov, Andrei, Vester-Blokland, Estelle, McQuade, Robert D., Crandall, David T., Carson, William H., Marcus, Ronald N., L'Italien, Gilbert
Publicado 2008